Research Studying Why Therapy Works for Some, Not Others

Interesting news: new lupus research will focus on why some therapies work well for some people with lupus, but not others.

The focus of the research study, from the University of Rochester Medical Center in Rochester, N.Y., is on B-cells. B-cells are considered “key combat-ready immune cells.” B-cells are also often responsible for manufacturing auto-antibodies. The research should also open up the way the immune system works and mechanisms behind lupus.

Researchers are specifically looking at how bone marrow produces B-cells, and what quality control checkpoints it imposes to ensure that only healthy cells are released into the bloodstream.

This quality control system breaks down in lupus patients, and B-cells produce auto-antibodies and attack the patient's own body. This leads to the myriad symptoms and complications lupus patients suffer, including inflammation and damage to joints, skin, and, in some cases, the heart, kidneys and brain.

One treatment is known as "B-cell depletion therapy.” This therapy reduces the number of B-cells in the patient's bloodstream. It was successful for some – and of those, the success was quite noticeable. Now study specialists are trying to determine why this therapy works so remarkably for some, but not others.

Discovering why should help create and direct future therapies for lupus patients.